Open Actively Recruiting

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

About

Brief Summary

COMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease (CAD) who have undergone successful culprit lesion Percutaneous Coronary Intervention (PCI).

COMPLETE-2 OCT is a large scale, prospective, multi-centre, observational, imaging study of patients with STEMI or NSTEMI and multivessel CAD in a subset of eligible COMPLETE-2 patients.

Primary Purpose
The main objective of the intervention(s) being evaluated by the clinical trial. Learn more
Treatment
Study Type
The nature of the investigation or investigational use for which clinical study information is being submitted. Learn more
Interventional
Phase
N/A

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

  • Patients presenting with STEMI or type 1 NSTEMI and within 72 hours of successful culprit-lesion PCI
  • Residual coronary artery disease defined as at least 1 additional non-infarct-related coronary artery stenosis that meets all of the following criteria:
    • Amenable to successful treatment with PCI
    • At least 50% diameter stenosis by visual estimation
    • At least 2.5 mm in diameter
  • Planned complete revascularization strategy for qualifying MI

Exclusion Criteria:

  • Planned or prior coronary artery bypass graft (CABG) surgery
  • Inability to clearly identify a culprit lesion for STEMI or NSTEMI based on angiographic appearance and/or ECG changes and/or regional wall motion abnormalities
  • Prior PCI of a non-culprit lesion in a different vessel from the culprit lesion within 45 days of randomization
  • Planned medical treatment of all qualifying non-culprit lesions (i.e., no PCI)
  • Presence of severe non-culprit-lesion stenosis with reduced epicardial flow (TIMI flow ≤ 2) or >90% visual diameter stenosis
  • Presence of a chronic total occlusion (CTO) if it is the only qualifying non-culprit lesion (patients with a CTO plus additional qualifying non-culprit lesions are eligible)
  • The only qualifying non-culprit lesion is in the same vessel territory as the culprit lesion
  • Baseline STEMI or NSTEMI was due to a suspected non-atherothrombotic mechanism such as type 2 MI (supply-demand mismatch), including spontaneous coronary artery dissection or coronary artery embolism
  • Non-cardiovascular co-morbidity with expected life expectancy <2 years
  • Any other medical, geographic, or social factor making study participation impractical or precluding 5 year follow-up
Study Stats
Protocol No.
23-000738
Category
Heart/Cardiovascular Diseases
Contact
  • Ladda Douangvila-Chhan
Location
  • UCLA Santa Monica
  • UCLA Westwood
For Providers
NCT No.
NCT05701358
For detailed technical eligibility, visit ClinicalTrials.gov.